Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019December 9, 2022 Alterity Therapeutics

Chairman’s Address to Shareholders 2019 AGM

2019

Post navigation

AGM 2019 Presentation

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Related Posts

Chairman’s Address to Shareholders 2020 Annual General Meeting

November 18, 2020December 9, 2022

Chairman’s Address 2022 Annual General Meeting

November 11, 2022May 23, 2023

Chairman’s Address 2021 Annual General Meeting

November 12, 2021December 9, 2022

Recent Posts

XBRL 30 June 2023 filed with the SEC
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065